# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

> **NCT07536269** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Neurocrine Biosciences** · enrollment: 20 (estimated)

## Conditions studied

- Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** Crinecerfont

## Key facts

- **NCT ID:** NCT07536269
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07536269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07536269, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07536269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*